Meta-analysis of safety and immunogenicity of DTaP-IPV-Hib-HepB hexavaccine / 中国生物制品学杂志

@#Objective To compare the differences of safety and immunogenicity of DTaP-IPV-Hib-HepB hexavaccine,DTaPIPV-Hib pentavaccine plus HepB single vaccine or DTaP-IPV-HepB pentavaccine plus Hib single vaccine,so as to provide a reference for the marketing and use of hexavaccine in China.Methods Randomized controlled trials(RCTs)of DTaP-IPVHib-HepB hexavaccine,DTaP triple vaccine,Hib,IPV and HepB vaccines published at home and abroad were searched.The safety and immunogenicity of the hexavaccine were evaluated by Meta-analysis using Revman 5.4.1 software.Results A total of 7 articles,8 RCTs and 3 429 subjects were included. Meta-analysis of safety showed that there was no significant difference in the incidence of injection site and systemic adverse reactions after vaccination with hexavaccine and pentavaccine plus single vaccine(P > 0. 05)except for induration at the inoculation site and crying. Meta-analysis of immunogenicity showed no significant difference in antibody indexes after vaccination with hexavaccine and pentavaccine plus single vaccine(P > 0. 05).Conclusion The safety and immunogenicity of DTaP-IPV-Hib-HepB hexavaccine in basic immunity was comparable to that of the control vaccine,and might be applied to infants and young children to prevent related diseases. However,due to the limitations of the quantity and quality of included studies,the above conclusions still depend on the further development of larger sample,multicenter and high-quality

miR-4465 inhibits the malignant biological behaviors of hepatocellular carcinoma Hep3B cells by targeting and downregulating the expression of HMGA1 / 中国肿瘤生物治疗杂志

@#[摘 要] 目的：探讨miR-4465靶向高迁移率族蛋白A1（HMGA1）对肝细胞癌Hep3B细胞增殖、迁移和侵袭能力的影响。方法：收集2020年5月至2021年9月在皖南医学院第一附属医院确诊为肝细胞癌患者的16对癌组织和癌旁组织样本，采用qPCR分析miR-4465在肝细胞癌组织和Hep3B、Huh7细胞中的表达情况，双荧光素酶报告基因实验验证miR-4465与HMGA1的调控关系。按转染物的不同将Hep3B细胞分为mimics-NC组、miR-4465-mimics组、inhibitor-NC组、miR-4465 inhibitor组、si-NC组、si-HMGA1组；另外分组转染mimics-NC+pcDNA-NC、miR-4465 mimics+pcDNA-NC和miR-4465 mimics+pcDNA-HMGA1进行回复实验。采用qPCR和WB法检测各组细胞中HMGA1 mRNA和蛋白水平的变化，CCK-8法检测各组细胞增殖能力的变化，划痕实验检测各组细胞迁移能力的变化，Transwell实验检测各组细胞侵袭能力的变化。结果：miR-4465在肝细胞癌组织和细胞中的表达水平显著低于癌旁组织和正常肝细胞（P<0.05或P<0.001）。转染48 h后，过表达miR-4465的Hep3B细胞增殖、迁移和侵袭能力均显著下降（P<0.05、P<0.01或P<0.001）；敲低miR-4465后细胞的增殖、迁移和侵袭能力均明显升高（P<0.05、P<0.01或P<0.001）。双荧光素酶报告实验验证了HMGA1-3'UTR与miR-4465的靶向结合关系，miR-4465可以靶向下调HMGA1 mRNA和蛋白质的表达（均P<0.01）。过表达HMGA1能部分逆转过表达miR-4465对细胞增殖、迁移、侵袭的抑制作用及HMGA1表达的抑制作用（均P<0.05）。结论：miR-4465通过靶向下调HMGA1在肝细胞癌Hep3B细胞中的表达，从而抑制Hep3B细胞的恶性生物学行为。